Navigation Links
Georgia Tech/Emory Center to study origin of life
Date:9/18/2007

ar to proteins and DNA, that are essential for life to exist.

"We are particularly excited about the outreach projects of the center that involve college and high school students," said Hud. "The origin of life is one of the most intriguing questions of all time and one that can certainly attract young people to the field of chemistry, an area of national need."

"The creation of this center in Atlanta also provides us outreach opportunities for dialogue and discussion around some of the more divisive issues between science and religion and the origin of life,"said Lynn.

"It's a big puzzle," said Hud. "We will be looking at several chemical hypotheses regarding the origin of life. We want to understand the formation of the first lifelike polymers, and from that point understand the evolution of these polymers into something that could have given rise to life as we know it."


'/>"/>

Contact: David Terraso
d.terraso@gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Georgia Tech accelerates drug discovery with new IBM supercomputing cluster
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
5. $6.5 Million Grant for Microarray Center at Yale School of Medicine
6. Woods Hole Research Center plans controlled burn in Amazon rainforest
7. NIH creates nationwide network of molecular libraries screening centers
8. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
9. Center releases new public survey on stem cells
10. New study pinpoints epicenters of Earths imminent extinctions
11. World Trade Center identifications pushed forensic DNA technology
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5